Transcription of HYBRIDOMA TECHNOLOGY FOR PRODUCTION OF …
{{id}} {{{paragraph}}}
Example: barber
HYBRIDOMA TECHNOLOGY FOR PRODUCTION OF …
Volume 1, Issue 2, March April 2010; Article 017 ISSN 0976 044X International Journal of Pharmaceutical Sciences Review and Research Page 88 Available online at HYBRIDOMA TECHNOLOGY FOR PRODUCTION OF MONOCLONAL ANTIBODIES Shivanand Pandey Smt. R. B. P. M. Pharmacy College, Atkot-360040, Rajkot, Gujarat. India Email: ABSTRACT Hybridomas are cells that have been engineered to produce a desired antibody in large amounts. To produce monoclonal antibodies, B-cells are removed from the spleen of an animal that has been challenged with the relevant antigen. These B-cells are then fused with myeloma tumor cells that can grow indefinitely in culture (myeloma is a B-cell cancer). This fusion is performed by making the cell membranes more permeable. The fused hybrid cells (called hybridomas), being cancer cells, will multiply rapidly and indefinitely and will produce large amounts of the desired antibodies.
flasks. This maintains the well being of the hybridomas and provides enough cells for cryopreservation and supernatant for subsequent investigations. The culture supernatant can yield 1to 60 ug/ml of monoclonal antibody, which is maintained at 20°C or lower until required (Nelson et al., 2000.)By using culture supernatant
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: